D-0299-2022 Class I Terminated
FDA drug recall D-0299-2022 was initiated by Gilead Sciences, Inc. on December 3, 2021 and is designated Class I. Reason for recall: Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates. The recall status is terminated (terminated July 25, 2022). Affected quantity: 53,473 vials.
Recall Details
- Product Type
- Drugs
- Report Date
- January 5, 2022
- Initiation Date
- December 3, 2021
- Termination Date
- July 25, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 53,473 vials
Product Description
Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2
Reason for Recall
Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.
Distribution Pattern
Nationwide in the USA
Code Information
Lots: 2141001-1A, 2141002-1A, Exp. 01/2024